Bryan Silvey
Vice President, Head of Quality
Bryan Silvey joined A2 Biotherapeutics in 2021. He leads the Quality function for the company. Bryan has over 30 years’ experience in the pharma/biotech industry, encompassing broad management in Quality and GxP compliance with global regulatory agencies and Boards of Health.
Before joining A2 Bio, Bryan served as Senior Director, Global Quality Compliance, Kite (a Gilead Company). In this role, he oversaw the execution of quality/compliance requirements from late stage clinical to successful global launch of the company’s first commercial CAR T-cell therapy product in the US/EU/Canada, YESCARTA® (axicabtagene ciloleucel). This was shortly followed by the Kite’s second global launch of a CAR T-cell therapy, TECARTUS® (brexucabtagene autoleucel).
Previously, Bryan held senior leadership roles in Global Quality, and Regulatory Affairs CMC with Baxter Healthcare spin-off Baxalta (acquired by Shire in 2016). He holds a Bachelor of Science degree in Chemistry from Colorado State University.